Abstract 155P
Background
Despite the increasing application of robotic surgery in patients with gastric cancer, however, for the complex minimally invasive total gastrectomy, no reports are supporting robotic surgery that can improve surgical performance and clinical outcomes.
Methods
In this prospective study, 50 patients were assigned to underwent robotic total gastrectomy (RTG) between March 2018 to February 2020 at a tertiary referral teaching hospital. Patients who underwent laparoscopic total gastrectomy (LTG) in the FUGES-002 study were matched to compare the surgical outcome and surgery task load of RTG and LTG. Objective structured assessment of technical skill (OSATS) was used to evaluate the technical performance.
Results
After propensity score matching, 48 patients in the RTG group and 96 patients in the LTG group were included in the analysis. The total operative time in the RTG group was longer than that in LTG Group (217.1 minutes vs. 186.1 minutes, P < 0.001). Compared with LTG, the RTG group had less intraoperative blood loss (66.4 ml vs. 38.7 ml, P = 0.042). The average number of errors in the RTG group was 43.2 times/case, which was less than 53.8 times/case in the LTG Group (P < 0.001). Compared with LTG, RTG had a higher OSATS score (30.2 vs. 28.4, P < 0.001). RTG is superior to LTG in terms of respect for tissue, time and motion, instrument handling, and knowledge of specific procedures. The mean number of lymph nodes (LNs) retrieved in the RTG group and LTG group was 47.9 and 44.0, respectively. Significantly more extraperigastric LNs were retrieved in the RTG group than in the LTG group (20.2 vs. 17.5, P = 0.039). RTG group had a lower Surg-TLX score than LTG Group (33.2 vs. 39.8, P < 0.001). The postoperative recovery processes in the RTG group were shorter than those in the LTG Group. No significant difference was found between the RG and LG groups in the incidence (14.6% vs 16.7%, P = .86) or severity of complications.
Conclusions
In the complex radical gastrectomy, compared with traditional laparoscopic surgery, the use of the robotic system provides a technically superior operative environment and lower surgeon workload for minimally invasive surgery.
Clinical trial identification
NCT03524287.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session